Ally Bridge Group announced it has made investments in two European biopharmas: Galenica AG of Switzerland, and Nabriva , an Austrian-US pharma. Galenica's subsidiary Vifor Pharma, makes iron supplements and other products for chronic kidney disease. Nabriva develops next-gen antibiotics for bacterial infections, especially drug-resistant bacteria. Ally has $1.5 billion under management, all in life science companies, which are located in the US, Europe and China. It did not disclose the size of either investment.
